Nexviadyme 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
II/0008 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
30/11/2023 
SmPC and PL 
new quality, preclinical, clinical or pharmacovigilance 
data 
II/0012 
C.I.13 - Other variations not specifically covered 
16/11/2023 
n/a 
elsewhere in this Annex which involve the submission 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
of studies to the competent authority 
IB/0011 
B.I.a.3.e - Change in batch size (including batch size 
31/08/2023 
n/a 
ranges) of AS or intermediate - The scale for a 
biological/immunological AS is increased/decreased 
without process change (e.g. duplication of line) 
PSUSA/11002
Periodic Safety Update EU Single assessment - 
31/08/2023 
n/a 
PRAC Recommendation - maintenance 
/202302 
avalglucosidase alfa 
IA/0013 
B.II.e.7.a - Change in supplier of packaging 
01/08/2023 
n/a 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
IA/0010/G 
This was an application for a group of variations. 
24/05/2023 
Annex II 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IAIN/0007 
A.1 - Administrative change - Change in the name 
05/04/2023 
and/or address of the MAH 
SmPC, 
Labelling and 
PL 
PSUSA/11002
Periodic Safety Update EU Single assessment - 
16/03/2023 
n/a 
PRAC Recommendation - maintenance 
/202208 
avalglucosidase alfa 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0006 
B.I.a.2.z - Changes in the manufacturing process of 
21/12/2022 
n/a 
the AS - Other variation 
IB/0005/G 
This was an application for a group of variations. 
22/11/2022 
n/a 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
II/0003/G 
This was an application for a group of variations. 
06/10/2022 
n/a 
B.II.d.1.f - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
specification parameter which may have a significant 
effect on the overall quality of the finished product 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
B.I.b.1.e - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a 
specification parameter which may have a significant 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
effect on the overall quality of the AS and/or the FP 
II/0002 
B.I.a.3.c - Change in batch size (including batch size 
22/09/2022 
n/a 
ranges) of AS or intermediate - The change requires 
assessment of the comparability of a 
biological/immunological AS 
II/0001 
B.I.a.1.e - Change in the manufacturer of AS or of a 
22/09/2022 
n/a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
biological/immunological product 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
